Thanks. Does LZG have enough money to pay up?

Latest $GNS news - Genius Group Buys Back 6,600,000 Company Shares. First Tranche Completes 50% of Board-Authorised Mandate. Up to 43.3 Million Shares Targeted for Removal from Issued Capital. SINGAPORE, June 15, 2026 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) ("Genius Group", "GNS" or the "Company"), a leading AI-powered education group, today announced that it has bought back 6,600,000 Class A Ordinary Shares in a privately negotiated off-market transaction with a non-affiliated private holder, representing 50% of the 13.2 million share buyback authorised by the Company’s Board of Directors on June 7, 2026. The repurchase was executed in a privately negotiated transaction at a price below the recent trading price of the Company’s Class A Ordinary Shares on the NYSE American, providing immediate accretion to the Company’s Net Asset Value per Share (“NAVPS”) for the benefit of remaining shareholders. Further to the buyback, the Company will cancel the 6,600,000 shares in accordance with applicable Singapore and U.S. requirements, reducing the Company’s issued share capital accordingly. Roger James Hamilton, Founder and CEO of Genius Group, said “This buyback advances our capital allocation strategy of building shareholder value through Net Asset Value per Share (NAVPS)." "Genius Group currently trades at a meaningful discount to its NAVPS, and the Board and management are committed to taking disciplined, value-accretive actions to narrow that discount over time, including through further buybacks and share cancellations.” Path to a Further 36.7 Million Share Reduction Following today’s transaction, the Company has identified an aggregate of up to 36.7 million additional Class A Ordinary Shares targeted for removal from issued capital, comprising: >> 6.6 million shares authorised but not yet repurchased under the shareholder-approved mandate; and >> 30.1 million shares previously identified by the Company through its ERL Share Count Exercise and ICC arbitration proceedings as targeted for retirement or removal, subject to the relevant legal and regulatory processes. Taken together with the 6,600,000 shares cancelled today, this represents up to 43.3 million shares, which is equivalent to approximately 36% of the Company’s public float. The Company is targeting to continue to remove these shares from its issued share capital over time. While the timing and amount of any further repurchases or cancellations cannot be assured, the Company intends to act diligently to complete as much of the remaining mandate as practical prior to its expiry on July 6, 2026. At the Company’s Annual General Meeting on July 7, 2026, shareholders will be invited to approve a further buyback mandate of up to 20% of the Company’s issued Class A Ordinary Shares, valid for the following twelve months. Details of the AGM are available in the Company’s SEC filings. Full PR - ir.geniusgroup.net/news-even…

50% enrollment complete in Quantum BioPharma’s MS imaging study. Issued on behalf of @QuantumBP $QNTM Early scans show signal in MS lesions using a method designed to track myelin damage. What’s the one thing you’d want to see confirmed from here?

$QNTM share count keeps going up. Shares outstanding: May 7th = 6,398,605 June 1st = 7,197,455 (12.5% increase) @zsaeed and @AnthonyDurkacz keep diluting shareholders. @Malone_Wealth

$QNTM has now missed the deadline by 6 days. I swear @zsaeed and @AnthonyDurkacz don’t even work most days. @Malone_Wealth

Another month, another missed deadline by $QNTM. Deadline for its May progress report was 4 days ago. Still waiting. Why is this company seemingly incapable of making these filings on time? @zsaeed @Malone_Wealth @AnthonyDurkacz

$QNTM outstanding share count keeps climbing. There are now 6.27M shares outstanding. Over the past 2 months, the share count has risen by 43%. @zsaeed @Malone_Wealth @justinbrewer33

$QNTM still hasn’t published its monthly progress report. Deadline was 7 days ago. @RetailUnitedFin

$GNS proposed R/S up to 1-to-10 ratio. Makes sense why Roger converted his shares to supervoting shares now, doesn't it?

Sure would be nice if $QNTM published its monthly progress report on time for once. It’s due within the next hour. @zsaeed @AnthonyDurkacz @Malone_Wealth

It's going to be really funny when @beartrapmovie covers this one day lol

I have stake in $QNTM so I'm just being cautious. But you're in for a ride!

Brutal update from $QNTM: 1. “QNTM is withdrawing previously disclosed timelines relating to FDA review, start of the planned Phase 2 trial, and expected interim data milestones. Such timelines shall no longer be relied upon..” 2. Lead scientist resigned @zsaeed @Malone_Wealth

$QNTM Quantum BioPharma's MS drug Lucid-21-302 hit an FDA clinical hold on May 28. All Phase 2 trial timelines and data milestones are now withdrawn. Do not rely on previous guidance. A director also resigned the same day. Company says it believes the issues are addressable, but there's no timeline for resolution. Small-cap biopharma with no approved products. Treat accordingly. Not financial advice.